Emerging immunotherapy for the treatment of esophageal cancer

Seung Ju Jackie Oh, Songhee Han, Wooin Lee, Albert Lockhart

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Introduction: Esophageal cancer is the third most common cancer of the gastrointestinal tract. Despite new therapies, the prognosis for patients with these cancers remains poor with 5-year survival rates lower than 15%. Recently, immunotherapy has increasingly gained attention as a novel treatment strategy for advanced esophageal cancer. Areas covered: Recent success of immunotherapy in treating other solid tumors has shed light on the utility of these approaches for esophageal cancers. Here, the authors focus on antibody-based, adoptive-cell-therapy-based, and vaccine-based immunotherapies, and briefly address their rationale, clinical data, and implications. Expert opinion: Immunotherapy is now established to be a key treatment modality that can improve the outcomes of many cancer patients and appears to be ushering in a new era in cancer treatment. Checkpoint inhibitor drugs have shown preliminary favorable results in esophageal cancer treatment. Adoptive cell therapy and vaccine studies have also shown some promise in various clinical studies. Future endeavors will need to focus on identifying patients who are likely to benefit from immunotherapy, monitoring and managing immune responses and designing optimal combination strategies where immunotherapy agents are combined with other traditional treatment modalities.

Original languageEnglish (US)
Pages (from-to)667-677
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume25
Issue number6
DOIs
StatePublished - Jun 2 2016
Externally publishedYes

Fingerprint

Esophageal Neoplasms
Immunotherapy
Cell- and Tissue-Based Therapy
Neoplasms
Therapeutics
Vaccines
Immunologic Monitoring
Gastrointestinal Neoplasms
Expert Testimony
Survival Rate
Antibodies
Pharmaceutical Preparations

Keywords

  • adoptive cell therapy
  • antibody
  • cancer vaccine
  • esophageal cancer
  • Immunotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Emerging immunotherapy for the treatment of esophageal cancer. / Jackie Oh, Seung Ju; Han, Songhee; Lee, Wooin; Lockhart, Albert.

In: Expert Opinion on Investigational Drugs, Vol. 25, No. 6, 02.06.2016, p. 667-677.

Research output: Contribution to journalReview article

Jackie Oh, Seung Ju ; Han, Songhee ; Lee, Wooin ; Lockhart, Albert. / Emerging immunotherapy for the treatment of esophageal cancer. In: Expert Opinion on Investigational Drugs. 2016 ; Vol. 25, No. 6. pp. 667-677.
@article{e7edfa35cab243ce8689dc6f3e1000dd,
title = "Emerging immunotherapy for the treatment of esophageal cancer",
abstract = "Introduction: Esophageal cancer is the third most common cancer of the gastrointestinal tract. Despite new therapies, the prognosis for patients with these cancers remains poor with 5-year survival rates lower than 15{\%}. Recently, immunotherapy has increasingly gained attention as a novel treatment strategy for advanced esophageal cancer. Areas covered: Recent success of immunotherapy in treating other solid tumors has shed light on the utility of these approaches for esophageal cancers. Here, the authors focus on antibody-based, adoptive-cell-therapy-based, and vaccine-based immunotherapies, and briefly address their rationale, clinical data, and implications. Expert opinion: Immunotherapy is now established to be a key treatment modality that can improve the outcomes of many cancer patients and appears to be ushering in a new era in cancer treatment. Checkpoint inhibitor drugs have shown preliminary favorable results in esophageal cancer treatment. Adoptive cell therapy and vaccine studies have also shown some promise in various clinical studies. Future endeavors will need to focus on identifying patients who are likely to benefit from immunotherapy, monitoring and managing immune responses and designing optimal combination strategies where immunotherapy agents are combined with other traditional treatment modalities.",
keywords = "adoptive cell therapy, antibody, cancer vaccine, esophageal cancer, Immunotherapy",
author = "{Jackie Oh}, {Seung Ju} and Songhee Han and Wooin Lee and Albert Lockhart",
year = "2016",
month = "6",
day = "2",
doi = "10.1517/13543784.2016.1163336",
language = "English (US)",
volume = "25",
pages = "667--677",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Emerging immunotherapy for the treatment of esophageal cancer

AU - Jackie Oh, Seung Ju

AU - Han, Songhee

AU - Lee, Wooin

AU - Lockhart, Albert

PY - 2016/6/2

Y1 - 2016/6/2

N2 - Introduction: Esophageal cancer is the third most common cancer of the gastrointestinal tract. Despite new therapies, the prognosis for patients with these cancers remains poor with 5-year survival rates lower than 15%. Recently, immunotherapy has increasingly gained attention as a novel treatment strategy for advanced esophageal cancer. Areas covered: Recent success of immunotherapy in treating other solid tumors has shed light on the utility of these approaches for esophageal cancers. Here, the authors focus on antibody-based, adoptive-cell-therapy-based, and vaccine-based immunotherapies, and briefly address their rationale, clinical data, and implications. Expert opinion: Immunotherapy is now established to be a key treatment modality that can improve the outcomes of many cancer patients and appears to be ushering in a new era in cancer treatment. Checkpoint inhibitor drugs have shown preliminary favorable results in esophageal cancer treatment. Adoptive cell therapy and vaccine studies have also shown some promise in various clinical studies. Future endeavors will need to focus on identifying patients who are likely to benefit from immunotherapy, monitoring and managing immune responses and designing optimal combination strategies where immunotherapy agents are combined with other traditional treatment modalities.

AB - Introduction: Esophageal cancer is the third most common cancer of the gastrointestinal tract. Despite new therapies, the prognosis for patients with these cancers remains poor with 5-year survival rates lower than 15%. Recently, immunotherapy has increasingly gained attention as a novel treatment strategy for advanced esophageal cancer. Areas covered: Recent success of immunotherapy in treating other solid tumors has shed light on the utility of these approaches for esophageal cancers. Here, the authors focus on antibody-based, adoptive-cell-therapy-based, and vaccine-based immunotherapies, and briefly address their rationale, clinical data, and implications. Expert opinion: Immunotherapy is now established to be a key treatment modality that can improve the outcomes of many cancer patients and appears to be ushering in a new era in cancer treatment. Checkpoint inhibitor drugs have shown preliminary favorable results in esophageal cancer treatment. Adoptive cell therapy and vaccine studies have also shown some promise in various clinical studies. Future endeavors will need to focus on identifying patients who are likely to benefit from immunotherapy, monitoring and managing immune responses and designing optimal combination strategies where immunotherapy agents are combined with other traditional treatment modalities.

KW - adoptive cell therapy

KW - antibody

KW - cancer vaccine

KW - esophageal cancer

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84961390892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961390892&partnerID=8YFLogxK

U2 - 10.1517/13543784.2016.1163336

DO - 10.1517/13543784.2016.1163336

M3 - Review article

C2 - 26950826

AN - SCOPUS:84961390892

VL - 25

SP - 667

EP - 677

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 6

ER -